KV Emerging From Bankruptcy As Makena Sales Pick Up Steam
This article was originally published in The Pink Sheet Daily
Executive Summary
KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.
You may also be interested in...
Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns
Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.
AMAG Spends $700 Million To Better Sell Makena
Purchase of Cord Blood Registry is expected to boost commercialization of preterm birth drug Makena, while adding a stable growth business to AMAG and offering cost synergies.
AMAG Pursues Expanded Feraheme Strategy Through Lumara Deal
The biotech is acquiring privately held Lumara and its women’s health product Makena in hopes of using the salesforce once it expands the indication for its I.V. iron product Feraheme into that market.